View ValuationGenelux 향후 성장Future 기준 점검 5/6Genelux은 연간 수입과 매출이 각각 63.9%와 63.8% 증가할 것으로 예상되고 EPS는 연간 62.9%만큼 증가할 것으로 예상됩니다.핵심 정보63.9%이익 성장률62.94%EPS 성장률Biotechs 이익 성장25.4%매출 성장률63.8%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트13 May 2026최근 향후 성장 업데이트Breakeven Date Change • May 11Forecast to breakeven in 2028The 6 analysts covering Genelux expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.28m in 2028. Average annual earnings growth of 54% is required to achieve expected profit on schedule.Price Target Changed • Mar 20Price target decreased by 9.5% to US$17.50Down from US$19.33, the current price target is an average from 6 analysts. New target price is 629% above last closing price of US$2.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$0.95 last year.Price Target Changed • Oct 21Price target increased by 7.4% to US$19.33Up from US$18.00, the current price target is an average from 6 analysts. New target price is 188% above last closing price of US$6.72. Stock is up 158% over the past year. The company is forecast to post a net loss per share of US$0.88 next year compared to a net loss per share of US$0.95 last year.Price Target Changed • Jun 05Price target increased by 11% to US$20.00Up from US$18.00, the current price target is an average from 4 analysts. New target price is 691% above last closing price of US$2.53. Stock is up 0.4% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$0.95 last year.Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.89 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.892 to -US$0.885 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$18.80 to US$18.40. Share price fell 16% to US$2.46 over the past week.Price Target Changed • Oct 29Price target decreased by 9.6% to US$18.80Down from US$20.80, the current price target is an average from 5 analysts. New target price is 508% above last closing price of US$3.09. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.16 last year.모든 업데이트 보기Recent updatesNew Risk • May 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$28m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$28m free cash flow). Revenue is less than US$1m (US$8.0k revenue). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).Breakeven Date Change • May 11Forecast to breakeven in 2028The 6 analysts covering Genelux expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.28m in 2028. Average annual earnings growth of 54% is required to achieve expected profit on schedule.공시 • May 01Genelux Corporation, Annual General Meeting, Jun 16, 2026Genelux Corporation, Annual General Meeting, Jun 16, 2026. Location: edge.media-server.com/mmc/p/j3zspvj4, United StatesNew Risk • Mar 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).Price Target Changed • Mar 20Price target decreased by 9.5% to US$17.50Down from US$19.33, the current price target is an average from 6 analysts. New target price is 629% above last closing price of US$2.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$0.95 last year.공시 • Mar 20+ 1 more updateGenelux Corporation has completed a Follow-on Equity Offering in the amount of $100 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,460 Transaction Features: At the Market OfferingNew Risk • Jan 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 30% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (30% increase in shares outstanding). Significant insider selling over the past 3 months (US$106k sold).공시 • Jan 08+ 1 more updateGenelux Corporation has completed a Follow-on Equity Offering in the amount of $20.000001 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $20.000001 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: $3 Discount Per Security: $0.21New Risk • Jan 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Significant insider selling over the past 3 months (US$106k sold).공시 • Jan 06Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer TrialsGenelux Corporation announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 - evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and progressive non-small cell lung cancer (NSCLC), respectively, after failure of prior platinum-based regimens. Together, the open-label studies are designed to demonstrate that the Olvi-Vec-primed immunochemotherapy mechanism of resensitizing tumors to platinum-based chemotherapy can extend beyond intraperitoneal delivery into a systemic delivery setting across multiple solid tumor types. Platinum-relapsed or platinum-refractory advanced SCLC (OLVI-VEC-SCLC-202 Ph1b/2 Clinical Trial) The open-label Phase 1b/2 SCLC trial (NCT07136285) is evaluating a single intravenous cycle with multiple doses of Olvi-Vec administered in combination with platinum and etoposide chemotherapy in SCLC patients with platinum-relapsed or platinum-refractory disease after failing previous treatment with platinum and etoposide chemotherapy. The trial is being conducted by the Company’s licensing partner, Newsoara HYK Biopharmaceuticals Co. Ltd. (Newsoara), in China. As of the data review cutoff date of December 23, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 9 evaluable patients Overall response rate (ORR) of 33% (3/9 patients), including three PRs Two of the three PRs occurred in Cohort 4, the highest dose cohort tested as of the data review cutoff date, with tumor shrinkage of approximately 55% and 85% from baseline, representing an ORR of 67% (2/3) in Cohort 4 and potentially suggesting a dose-response trend Disease control rate (DCR) of 67% (6/9 patients) Tumor shrinkage of 24–85% among the six DCR patients, all of whom experienced a reduction in all target lesions from baseline Olvi-Vec generally well tolerated Exploratory durability signals: Two PR patients across different cohorts have been evaluated in long-term follow-up: A patient with 1 prior line, at last scan, achieved a PR with an ongoing progression-free survival (PFS) of 12.1 months A patient with 4 prior lines had a PFS of 7.7 months, which exceeds the PFS in the immediately preceding line in the same patient (1.9 months) by 5.8 months Notably, this SCLC trial is primarily evaluating safety and tolerability and, as such, patients who achieved objective responses from Olvi-Vec immunochemotherapy in this trial do not receive any subsequent standard maintenance immunotherapy to extend durability of response. Advanced or metastatic recurrent NSCLC (Phase 2 VIRO-25 Clinical Trial) The open-label Phase 2 VIRO-25 trial (NCT06463665) is evaluating a single intravenous cycle with multiple doses of Olvi-Vec in combination with platinum chemotherapy and an immune checkpoint inhibitor (ICI) in patients with advanced or metastatic recurrent NSCLC who failed standard frontline treatment of platinum chemotherapy and an ICI. The trial is being conducted in the United States. As of the data review cutoff date of December 31, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 5 evaluable patients DCR of 60% (3/5 patients) Tumor size changes among the three DCR patients were 8.9%, -18.9%, and -22.7%, respectively, as compared to baseline Olvi-Vec generally well tolerated Upcoming Milestones The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being conducted to align a systemic dosing regimen to support future multi-regional registrational clinical trials. Additional interim (updated dose-finding) data readouts expected throughout 2026 in Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial Topline data from the Phase 3 platinum-resistant/refractory ovarian cancer trial (OnPrime/GOG-3076) expected in second half of 2026.공시 • Jan 02Genelux Corporation Announces Change of Chief Medical OfficerOn December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the “Company”), effective immediately. On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company’s Chief Medical Officer, effective as of January 2, 2026 (the “Effective Date”). Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities. Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines. From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics Inc. where he built and led Artiva’s clinical and regulatory functions. During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships. From January 2019 to June 2019, Dr. Litten served as Chief Medical Officer at Optera Therapeutics Corp., and from September 2016 to May 2018, Dr. Litten was the Vice President of Clinical Development overseeing solid tumor programs at Juno Therapeutics Inc. Before Juno, he was Vice President of Clinical Development at Clovis Oncology Inc. Dr. Litten started his industry career in Oncology Clinical Development at Amgen Inc. Dr. Litten holds a B.S. in Finance and Economics from Cornell University and M.D. from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern Medical Center at Dallas.New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change).Price Target Changed • Oct 21Price target increased by 7.4% to US$19.33Up from US$18.00, the current price target is an average from 6 analysts. New target price is 188% above last closing price of US$6.72. Stock is up 158% over the past year. The company is forecast to post a net loss per share of US$0.88 next year compared to a net loss per share of US$0.95 last year.공시 • Jul 14Genelux Corporation, Annual General Meeting, Aug 27, 2025Genelux Corporation, Annual General Meeting, Aug 27, 2025.공시 • Jul 07Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business DevelopmentGenelux Corporation announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. Mr. Groen is an accomplished executive who has over two decades of leadership in the life sciences industry, driving results, empowering teams, and shaping positive corporate culture. Recognized as a strategic yet hands-on executive, he is passionate about advancing innovation to improve patient outcomes and is eager to help Genelux realize the full potential of Olvi-Vec for patients, shareholders, and employees. Most recently, Mr. Groen served as General Counsel of Rani Therapeutics, a clinical-stage, publicly traded biotech company. Previously, he spent 20 years in the legal department at Amgen with a proven track record in business development transactions such as Amgen’s $10 billion acquisition of Onyx Pharmaceuticals. Mr. Groen offers deep expertise across corporate law, mergers and acquisitions, licensing, compliance, and business development. He graduated from Harvard Law School with his J.D. and from the University of California, Santa Barbara with a B.A. in Political Science.New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$23m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Significant insider selling over the past 3 months (US$78k sold).Price Target Changed • Jun 05Price target increased by 11% to US$20.00Up from US$18.00, the current price target is an average from 4 analysts. New target price is 691% above last closing price of US$2.53. Stock is up 0.4% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$0.95 last year.New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$46m net loss in 3 years). Market cap is less than US$100m (US$97.0m market cap).New Risk • Mar 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$46m net loss in 3 years).New Risk • Mar 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$37m net loss in 3 years). Share price has been volatile over the past 3 months (17% average weekly change).공시 • Mar 26+ 1 more updateGenelux Corporation and Newsoara BioPharma Co., Ltd. Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung CancerGenelux Corporation and Newsoara BioPharma Co. Ltd. announced preliminary safety and anti-tumor activity data from the dose escalation Phase 1b portion of the companies' co-sponsored ongoing Phase 1b/2 clinical trial (OLVI-VEC-SCLC-202) of Olvi-Vec immunochemotherapy in patients with platinum-relapsed or platinum-refractory extensive small cell lung cancer. Olvi-Vec-SCLC-202 is a Phase 1b/2, open-label, multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics and efficacy of intravenously delivered Olvi-Vec combined with platinum and etoposide in the treatment of platinum-relapsed or platinum -refractory extensive small cell Lung cancer patients. The Phase 1b trial is currently enrolling patients in China at Shanghai Chest Hospital, the lead clinical site, and Zhejiang Provincial People's Hospital. The Phase 2 portion of the trial is planned to follow and further evaluate the safety and tolerability as well as efficacy of Olvi-Vec at the recommended dose. Olvi-Vec (olvimulogene nanivacirepvec), Genelux's most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials.공시 • Mar 25Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory DiseaseGenelux Corporation announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/refractory ovarian cancer (PRROC). Currently, Olvi-Vec is being evaluated in the OnPrime/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471). The purpose of the FDA meeting was to discuss the FDA's expectations with respect to the requirements necessary for the granting of traditional approval of Olvi-Vec. In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing On Prime/GOG-3076 trial, the FDA responded that "As stated previously, an interim analysis of overall survival (OS) should be planned at the time of the primary PFS analysis. If a clinically meaningful PFS advantage is demonstrated in the absence of a decreement in OS, this could potentially support traditional approval. The FDA further recommended Genelux request a pre-BLA meeting with FDA with topline safety and efficacy data following completion of the study to discuss next steps. The inclusion criteria allows patients to enroll regardless of (i) tumor biomarkers, (ii) platinum refractory tumors or (iii) the maximum number of prior lines of treatments (i.e., no cap on previous treatments). Olvi-Vec (olvimulogene nanivacirepvec), Genelux's most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials. Olvi-Vec has be granted Fast Track designation by the US FDA for the treatment of platinum resistant/refractory ovarian cancer.분석 기사 • Feb 13Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Feb 03Genelux Corporation Appoints Matthew Pulisic as Chief Financial OfficerGenelux Corporation announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. Mr. Pulisic is an accomplished, senior executive with over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia. He is recognized for his expertise in financial leadership, corporate strategy and operational execution.Most recently, Mr. Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company. He played a key role in shaping the company’s financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company’s evolution from a clinical-stage to a pre-commercial organization. He began his career at Amgen, a publicly traded commercial biotechnology company, as a Research Associate and transitioned into finance where he held positions of increasing responsibility, across a breadth of finance-related positions, including Finance Director of Amgen Worldwide and Head of Capital Finance. He graduated from California Lutheran University with his M.B.A. in finance and from the University of California, Santa Cruz with his B.S. in Biochemistry and Molecular Biology.Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.89 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.892 to -US$0.885 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$18.80 to US$18.40. Share price fell 16% to US$2.46 over the past week.Seeking Alpha • Oct 31Genelux: H2 2025 PRROC Data Is A Major Inflection PointSummary Topline results from the phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer are expected in the second half of 2025. Interim data from the phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected in mid-2025. Interim results from the phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected second half of 2024. The global ovarian cancer treatment drugs market size is expected to reach $5.45 billion by 2033; About 85% of patients with ovarian cancer will experience recurrence at some point. Read the full article on Seeking AlphaPrice Target Changed • Oct 29Price target decreased by 9.6% to US$18.80Down from US$20.80, the current price target is an average from 5 analysts. New target price is 508% above last closing price of US$3.09. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.16 last year.공시 • Oct 25Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung CancerGenelux Corporation announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies. The VIRO-25 clinical trial (NCT06463665 [3]), is an open-label, randomized study in NSCLC designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of ICI compared with docetaxel in patients with advanced or metastatic NSCLC who have shown first disease progression while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care. Olvi-Vec’s previous data suggests a manageable safety profile, and this trial looks to further confirm the hypothesis that Olvi-Vec may resensitize to platinum in multiple tumor types. Genelux expects interim data readout in mid-2025.Recent Insider Transactions • Aug 29Insider recently sold US$200k worth of stockOn the 27th of August, Aladar Szalay sold around 92k shares on-market at roughly US$2.19 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$13m more than they bought in the last 12 months.분석 기사 • Aug 24We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Major Estimate Revision • Aug 21Consensus EPS estimates upgraded to US$0.88 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.957 to -US$0.88 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$23.50 unchanged from last update. Share price was steady at US$2.05 over the past week.New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$22m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (US$73.2m market cap).공시 • Jul 03+ 3 more updatesGenelux Corporation(NasdaqCM:GNLX) dropped from Russell Small Cap Comp Value IndexGenelux Corporation(NasdaqCM:GNLX) dropped from Russell Small Cap Comp Value Index공시 • Jun 18Genelux Corporation, Annual General Meeting, Aug 01, 2024Genelux Corporation, Annual General Meeting, Aug 01, 2024.공시 • May 25Genelux Corporation has completed a Follow-on Equity Offering in the amount of $27.5 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $27.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,875,000 Price\Range: $4 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,875,000공시 • May 24Genelux Corporation has filed a Follow-on Equity Offering.Genelux Corporation has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Security Name: Warrants Security Type: Equity WarrantReported Earnings • May 10First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.53 loss in 1Q 2023)First quarter 2024 results: US$0.29 loss per share (improved from US$0.53 loss in 1Q 2023). Net loss: US$7.85m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.Recent Insider Transactions • Apr 19Insider recently sold US$256k worth of stockOn the 17th of April, Aladar Szalay sold around 71k shares on-market at roughly US$3.59 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$13m more than they bought in the last 12 months.New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$93.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$170k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (US$93.0m market cap).Price Target Changed • Apr 03Price target decreased by 23% to US$26.00Down from US$33.75, the current price target is an average from 4 analysts. New target price is 435% above last closing price of US$4.86. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$1.16 last year.Reported Earnings • Mar 31Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.16 loss per share (further deteriorated from US$0.57 loss in FY 2022). Net loss: US$28.3m (loss widened 443% from FY 2022). Products in clinical trials Phase I: 3 Phase III: 1 Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 6.7%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.분석 기사 • Jan 29We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Dec 17Insider notifies of intention to sell stockYong Yu intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$13.16, it would amount to US$428k. Since March 2023, Yong's direct individual holding has decreased from 150.00k shares to 32.54k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Dec 10Insider recently sold US$436k worth of stockOn the 7th of December, Yong Yu sold around 37k shares on-market at roughly US$11.85 per share. This transaction amounted to 53% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.9m. Insiders have been net sellers, collectively disposing of US$12m more than they bought in the last 12 months.Recent Insider Transactions • Nov 24Insider recently sold US$210k worth of stockOn the 20th of November, Yong Yu sold around 18k shares on-market at roughly US$11.60 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.9m. Insiders have been net sellers, collectively disposing of US$12m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Nov 20Insider notifies of intention to sell stockYong Yu intends to sell 37k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of November. If the sale is conducted around the recent share price of US$13.02, it would amount to US$479k. Since March 2023, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Oct 27Insider recently sold US$998k worth of stockOn the 23rd of October, Aladar Szalay sold around 50k shares on-market at roughly US$19.97 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$1.9m. Insiders have been net sellers, collectively disposing of US$11m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Oct 26Insider notifies of intention to sell stockYong Yu intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of October. If the sale is conducted around the recent share price of US$19.42, it would amount to US$101k. Since December 2022, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Oct 12Insider notifies of intention to sell stockYong Yu intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of October. If the sale is conducted around the recent share price of US$23.79, it would amount to US$124k. Since December 2022, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Sep 27We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Sep 15Genelux Corporation Elects John Smither as Class I DirectorGenelux Corporation announced that at its 2023 Annual Meeting of Stockholders held on September 11, 2023, elected John Smither as Class I Director, to serve until the Company’s 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.Recent Insider Transactions • Sep 13Insider recently sold US$879k worth of stockOn the 8th of September, Aladar Szalay sold around 37k shares on-market at roughly US$23.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.New Risk • Sep 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$35m net loss in 3 years). Significant insider selling over the past 3 months (US$915k sold).Recent Insider Transactions • Aug 31Insider recently sold US$489k worth of stockOn the 30th of August, Yong Yu sold around 20k shares on-market at roughly US$24.70 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$914k more than they bought in the last 12 months.공시 • Aug 30Genelux Corporation Announces Executive ChangesOn August 28, 2023, Genelux Corporation announced the appointment of Lourie Zak as the Company’s Chief Financial Officer and the designation of Ms. Zak as the Company’s principal financial officer and principal accounting officer, in each case effective as of August 28, 2023 (the “Effective Date”). In connection with Ms. Zak’s appointment to the position of Chief Financial Officer, and as of the Effective Date, Thomas Zindrick, the Company’s President and Chief Executive Officer, will no longer serve as the Company’s principal financial officer, and Doug Samuelson, the Company’s former Chief Financial Officer, will no longer serve as the Company’s principal accounting officer. Ms. Zak, 60, most recently served as an Executive Consultant for CFO Assignments from March 2015 to August 2023. Ms. Zak previously served as the Chief Financial Officer of Guitar Center Brands of Guitar Center Inc. from October 2014 to January 2015 and the Chief Financial Officer of SONIFI Solutions Inc. from February 2013 to October 2014. Pursuant to the terms of Ms. Zak’s employment agreement (the “Zak Employment Agreement”), effective as of the Effective Date, Ms. Zak’s employment may be terminated at-will by either party, with or without notice, subject to the terms of the Zak Employment Agreement. Ms. Zak will receive a base salary of $360,000 per year and be eligible for an annual discretionary bonus with a target amount of up to 40% of her then-current base salary based on the achievement of certain performance goals determined by the Board of Directors of the Company. Subject to approval by the Board of Directors of the Company, Ms. Zak will be issued an option to purchase 150,000 shares of common stock of the Company with a per share exercise price equal to the fair market value on the date of grant (the “Option”). The shares subject to the Option will vest over four years of continuous service to the Company, with 25% of the shares subject to the Option vesting on the first-year anniversary of the Effective Date, and the remaining shares vesting in equal monthly installments over the subsequent 36 months of continuous service thereafter. In the event of a change in control, as defined in the Company’s 2022 Equity Incentive Plan, and subject to Ms. Zak’s continuous service through such change in control, 100% of the shares subject to the unvested portion of the Option will accelerate and vest in full. The Option shall be governed in all respects by the terms of the Company’s 2022 Equity Incentive Plan, as amended, and the option agreement between Ms. Zak and the Company. Ms. Zak will be entitled to receive severance benefits in the event her employment is terminated by the Company without cause or if she resigns for good reason, provided she remains in compliance with the terms of the Zak Employment Agreement. In the event of such termination or resignation, Ms. Zak will receive (i) severance in a lump sum equal to twelve months of her then-current base salary plus her full target annual bonus for the calendar year in which such separation occurs (but only in connection with a separation occurring during the period beginning three months before and ending 18 months following a change in control), and (ii) up to twelve months of COBRA group health insurance continuation. The foregoing severance benefits are conditioned upon Ms. Zak signing and not revoking a separation agreement and release of claims by no later than the 60th day after the employment termination.Recent Insider Transactions • Aug 24Chairman recently sold US$198k worth of stockOn the 18th of August, Thomas Zindrick sold around 8k shares on-market at roughly US$23.73 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Aug 21Chairman notifies of intention to sell stockThomas Zindrick intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of August. If the sale is conducted around the recent share price of US$23.90, it would amount to US$200k. Since September 2022, Thomas has not owned shares directly (This sale likely refers to shares that have not yet been received). There has only been one transaction (US$1.2k purchase) from insiders over the last 12 months.New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 9.2% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$17m net loss in 2 years).공시 • Jul 23Genelux Corporation, Annual General Meeting, Sep 11, 2023Genelux Corporation, Annual General Meeting, Sep 11, 2023, at 10:00 Pacific Standard Time. Location: 4500 Riverwalk Pkwy Riverside United States Agenda: To elect the one Class I director to hold office until the Company's 2026 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal; to ratify the selection by the Audit Committee of the Board of Directors of Weinberg & Company, P.A. as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023; and to conduct any other business properly brought before the Annual Meeting.공시 • Jul 16Genelux Notifies the Nasdaq Stock Market that it Was Not in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)Genelux Corporation announced that due to the vacancy resulting from Mr. Gabe Woodward's resignation, the Audit Committee of the Board is now comprised of two independent directors. As a result, on July 12, 2023, the Company notified The Nasdaq Stock Market LLC (Nasdaq") that it was not in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the Rule"), which requires an audit committee comprised of at least three members, each of whom must satisfy the requirements for audit committee members under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. The Company expects to receive a letter from Nasdaq to formally notify the Company of its non-compliance with the Rule. The Company intends to rely on the cure provision in Nasdaq Listing Rule 5605(c)(4)(B), and intends to regain compliance with the Rule prior to the expiration of the applicable cure period specified in Nasdaq Listing Rule 5605(c)(4)(B).공시 • Jul 15Genelux Announces Resignation of Gabe Woodward from the BoardOn July 10, 2023, Gabe Woodward notified the board of directors (the “Board”) of Genelux Corporation (the “Company”) of his decision to resign from the Board, effective July 12, 2023. Mr. Woodward’s resignation was made in the normal course of business at the request of his partnership now that the Company’s initial public offering has been completed, and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.공시 • Jul 11Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Frontiers in ImmunologyGenelux Corporation announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effort (MPE) due to either MPM or metastatic disease (non-small cell lung cancer or breast cancer). The study was completed at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density and increase in immune cell density, confirming the mechanism of action of both direct cytotoxic and immune-activating effects. Among all patients, median overall survival (OS) was 19.5 months. The median OS among patients who had malignant pleural mesothelioma (MPM) was 22 months. There were no dose-limiting toxicities or dose de-escalations, and the maximally tolerated dose was not reached. Therefore, a recommended dose was not established. Palliative interventions have traditionally been relied upon for alleviating symptoms and preventing the recurrence of MPE, which can disrupt cancer treatments for MPE patients. However, the effectiveness of systemic immune checkpoint inhibitor therapy, chemotherapy, or a combination of therapies in MPE patients has shown limited success. This Phase 1 clinical trial enrolled eighteen MPE patients [MPM (n=15), and metastatic breast or lung diseases (n=3), who underwent a dose escalating method of intrapleural administration of Olvi-Vec following drainage of MPE. The primary objective of this trial was to determine a recommended dose. The secondary objectives were to assess feasibility, safety and tolerability; evaluate viral presence in the tumor and serum as well as viral shedding in pleural fluid, sputum, and urine; and evaluate anti-vaccinia virus immune response. Treatment with Olvi-Vec at the dose of 1x107 plaque-forming units (PFU) to 6x109 PFU was feasible and safe, with no treatment-associated mortalities or dose-limiting toxicities. Olvi-Vec was detectable in tumor cells 2-5 days post-treatment, and treatment was associated with a decrease in tumor cell density and an increase in immune cell density as assessed by a pathologist blinded to the clinical observations. When matched tumor specimens were compared (n=4), tumor cell density score decreased from pre-treatment to post-treatment in all patients. Immune cell density score increased from pre-treatment to post-treatment in 3 of 4 patients.공시 • Jun 30Genelux Corporation and TVAX Biomedical, Inc. Announces the Issuance of A United States Patent Covering the Combination of an Adoptive T Cell Therapy/Oncolytic Viral Cancer TreatmentGenelux Corporation and TVAX Biomedical, Inc. announced that the United States Patent and Trademark Office granted a patent claims methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT Immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT Immunotherapy. The rationale for V2ACT Immunotherapy stems from compelling scientific evidence that vaccination generates an immune response which increases the number of neoantigen-specific T cells in the body and that Olvi-Vec induces an acute inflammatory response that increases cancer tissue receptivity for the clinical effects of adoptively transferred neoantigen-specific effector T cells. This generates compelling support for the view that V2ACT Immunotherapy may safely achieve superior efficacies against a wide range of cancers. V2ACT capitalizes on the lead assets of both Genelux and TVAX as a combination therapy. Olvi-Vec has demonstrated systemic immunomodulation, an excellent safety profile, powerful immune modulation of the cancer microenvironment and well-documented anti-cancer effects over a wide range of cancers both in preclinical and Phase 2 clinical trials. TVAX Immunotherapy provides a unique neoantigen-specific adoptive T cell therapy, with an excellent safety profile and powerful anti-cancer effects on a wide range of cancers demonstrated in preclinical and Phase 2 clinical trials.공시 • May 16Genelux Corporation announced that it expects to receive $33.30494 million in fundingGenelux Corporation announced a private placement to issue1,665,247 common shares at a price of $20.00 per share for the gross proceeds of approximately $33.30494 million. The initial closing of the private placement, in the amount of approximately $18 million in the aggregate, is expected to occur on or about May 19, 2023, subject to the satisfaction of customary closing conditions. Additional committed funds in the amount of approximately $15 million in the aggregate will be invested on or before November 15, 2023, at the same price as the initial closing investments.공시 • Jan 27Genelux Corporation has completed an IPO in the amount of $15 million.Genelux Corporation has completed an IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42이익 및 매출 성장 예측NasdaqCM:GNLX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202870-5N/AN/A512/31/202712-38N/A-38612/31/2026N/A-37N/A-2663/31/20260-34-28-26N/A12/31/20250-32-26-25N/A9/30/2025N/A-32-24-23N/A6/30/2025N/A-30-23-23N/A3/31/2025N/A-30-23-22N/A12/31/20240-30-22-21N/A9/30/20240-28-24-24N/A6/30/20240-27-22-21N/A3/31/20240-26-21-20N/A12/31/20230-28-21-20N/A9/30/20230-25-16-15N/A6/30/202311-15-15-14N/A3/31/202311-12-11-11N/A12/31/202211-5-4-4N/A9/30/202211-5-1-1N/A6/30/2022N/A-13-1-1N/A3/31/2022N/A-17-1-1N/A12/31/2021N/A-16-7-7N/A3/31/2021N/A-13-8-8N/A12/31/2020N/A-14-7-7N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GNLX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: GNLX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: GNLX 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: GNLX 의 수익(연간 63.8%)이 US 시장(연간 12.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: GNLX 의 수익(연간 63.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GNLX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/02 19:05종가2026/06/02 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genelux Corporation는 7명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bruce JacksonBenchmark CompanyBrian Kemp DolliverBrookline Capital MarketsEmily BodnarH.C. Wainwright & Co.4명의 분석가 더 보기
Breakeven Date Change • May 11Forecast to breakeven in 2028The 6 analysts covering Genelux expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.28m in 2028. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
Price Target Changed • Mar 20Price target decreased by 9.5% to US$17.50Down from US$19.33, the current price target is an average from 6 analysts. New target price is 629% above last closing price of US$2.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$0.95 last year.
Price Target Changed • Oct 21Price target increased by 7.4% to US$19.33Up from US$18.00, the current price target is an average from 6 analysts. New target price is 188% above last closing price of US$6.72. Stock is up 158% over the past year. The company is forecast to post a net loss per share of US$0.88 next year compared to a net loss per share of US$0.95 last year.
Price Target Changed • Jun 05Price target increased by 11% to US$20.00Up from US$18.00, the current price target is an average from 4 analysts. New target price is 691% above last closing price of US$2.53. Stock is up 0.4% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$0.95 last year.
Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.89 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.892 to -US$0.885 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$18.80 to US$18.40. Share price fell 16% to US$2.46 over the past week.
Price Target Changed • Oct 29Price target decreased by 9.6% to US$18.80Down from US$20.80, the current price target is an average from 5 analysts. New target price is 508% above last closing price of US$3.09. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.16 last year.
New Risk • May 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$28m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$28m free cash flow). Revenue is less than US$1m (US$8.0k revenue). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).
Breakeven Date Change • May 11Forecast to breakeven in 2028The 6 analysts covering Genelux expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.28m in 2028. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
공시 • May 01Genelux Corporation, Annual General Meeting, Jun 16, 2026Genelux Corporation, Annual General Meeting, Jun 16, 2026. Location: edge.media-server.com/mmc/p/j3zspvj4, United States
New Risk • Mar 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
Price Target Changed • Mar 20Price target decreased by 9.5% to US$17.50Down from US$19.33, the current price target is an average from 6 analysts. New target price is 629% above last closing price of US$2.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$0.95 last year.
공시 • Mar 20+ 1 more updateGenelux Corporation has completed a Follow-on Equity Offering in the amount of $100 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,460 Transaction Features: At the Market Offering
New Risk • Jan 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 30% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (30% increase in shares outstanding). Significant insider selling over the past 3 months (US$106k sold).
공시 • Jan 08+ 1 more updateGenelux Corporation has completed a Follow-on Equity Offering in the amount of $20.000001 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $20.000001 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: $3 Discount Per Security: $0.21
New Risk • Jan 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Significant insider selling over the past 3 months (US$106k sold).
공시 • Jan 06Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer TrialsGenelux Corporation announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 - evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and progressive non-small cell lung cancer (NSCLC), respectively, after failure of prior platinum-based regimens. Together, the open-label studies are designed to demonstrate that the Olvi-Vec-primed immunochemotherapy mechanism of resensitizing tumors to platinum-based chemotherapy can extend beyond intraperitoneal delivery into a systemic delivery setting across multiple solid tumor types. Platinum-relapsed or platinum-refractory advanced SCLC (OLVI-VEC-SCLC-202 Ph1b/2 Clinical Trial) The open-label Phase 1b/2 SCLC trial (NCT07136285) is evaluating a single intravenous cycle with multiple doses of Olvi-Vec administered in combination with platinum and etoposide chemotherapy in SCLC patients with platinum-relapsed or platinum-refractory disease after failing previous treatment with platinum and etoposide chemotherapy. The trial is being conducted by the Company’s licensing partner, Newsoara HYK Biopharmaceuticals Co. Ltd. (Newsoara), in China. As of the data review cutoff date of December 23, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 9 evaluable patients Overall response rate (ORR) of 33% (3/9 patients), including three PRs Two of the three PRs occurred in Cohort 4, the highest dose cohort tested as of the data review cutoff date, with tumor shrinkage of approximately 55% and 85% from baseline, representing an ORR of 67% (2/3) in Cohort 4 and potentially suggesting a dose-response trend Disease control rate (DCR) of 67% (6/9 patients) Tumor shrinkage of 24–85% among the six DCR patients, all of whom experienced a reduction in all target lesions from baseline Olvi-Vec generally well tolerated Exploratory durability signals: Two PR patients across different cohorts have been evaluated in long-term follow-up: A patient with 1 prior line, at last scan, achieved a PR with an ongoing progression-free survival (PFS) of 12.1 months A patient with 4 prior lines had a PFS of 7.7 months, which exceeds the PFS in the immediately preceding line in the same patient (1.9 months) by 5.8 months Notably, this SCLC trial is primarily evaluating safety and tolerability and, as such, patients who achieved objective responses from Olvi-Vec immunochemotherapy in this trial do not receive any subsequent standard maintenance immunotherapy to extend durability of response. Advanced or metastatic recurrent NSCLC (Phase 2 VIRO-25 Clinical Trial) The open-label Phase 2 VIRO-25 trial (NCT06463665) is evaluating a single intravenous cycle with multiple doses of Olvi-Vec in combination with platinum chemotherapy and an immune checkpoint inhibitor (ICI) in patients with advanced or metastatic recurrent NSCLC who failed standard frontline treatment of platinum chemotherapy and an ICI. The trial is being conducted in the United States. As of the data review cutoff date of December 31, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 5 evaluable patients DCR of 60% (3/5 patients) Tumor size changes among the three DCR patients were 8.9%, -18.9%, and -22.7%, respectively, as compared to baseline Olvi-Vec generally well tolerated Upcoming Milestones The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being conducted to align a systemic dosing regimen to support future multi-regional registrational clinical trials. Additional interim (updated dose-finding) data readouts expected throughout 2026 in Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial Topline data from the Phase 3 platinum-resistant/refractory ovarian cancer trial (OnPrime/GOG-3076) expected in second half of 2026.
공시 • Jan 02Genelux Corporation Announces Change of Chief Medical OfficerOn December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the “Company”), effective immediately. On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company’s Chief Medical Officer, effective as of January 2, 2026 (the “Effective Date”). Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities. Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines. From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics Inc. where he built and led Artiva’s clinical and regulatory functions. During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships. From January 2019 to June 2019, Dr. Litten served as Chief Medical Officer at Optera Therapeutics Corp., and from September 2016 to May 2018, Dr. Litten was the Vice President of Clinical Development overseeing solid tumor programs at Juno Therapeutics Inc. Before Juno, he was Vice President of Clinical Development at Clovis Oncology Inc. Dr. Litten started his industry career in Oncology Clinical Development at Amgen Inc. Dr. Litten holds a B.S. in Finance and Economics from Cornell University and M.D. from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern Medical Center at Dallas.
New Risk • Nov 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change).
Price Target Changed • Oct 21Price target increased by 7.4% to US$19.33Up from US$18.00, the current price target is an average from 6 analysts. New target price is 188% above last closing price of US$6.72. Stock is up 158% over the past year. The company is forecast to post a net loss per share of US$0.88 next year compared to a net loss per share of US$0.95 last year.
공시 • Jul 14Genelux Corporation, Annual General Meeting, Aug 27, 2025Genelux Corporation, Annual General Meeting, Aug 27, 2025.
공시 • Jul 07Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business DevelopmentGenelux Corporation announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. Mr. Groen is an accomplished executive who has over two decades of leadership in the life sciences industry, driving results, empowering teams, and shaping positive corporate culture. Recognized as a strategic yet hands-on executive, he is passionate about advancing innovation to improve patient outcomes and is eager to help Genelux realize the full potential of Olvi-Vec for patients, shareholders, and employees. Most recently, Mr. Groen served as General Counsel of Rani Therapeutics, a clinical-stage, publicly traded biotech company. Previously, he spent 20 years in the legal department at Amgen with a proven track record in business development transactions such as Amgen’s $10 billion acquisition of Onyx Pharmaceuticals. Mr. Groen offers deep expertise across corporate law, mergers and acquisitions, licensing, compliance, and business development. He graduated from Harvard Law School with his J.D. and from the University of California, Santa Barbara with a B.A. in Political Science.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$23m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Significant insider selling over the past 3 months (US$78k sold).
Price Target Changed • Jun 05Price target increased by 11% to US$20.00Up from US$18.00, the current price target is an average from 4 analysts. New target price is 691% above last closing price of US$2.53. Stock is up 0.4% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$0.95 last year.
New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$46m net loss in 3 years). Market cap is less than US$100m (US$97.0m market cap).
New Risk • Mar 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$46m net loss in 3 years).
New Risk • Mar 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$37m net loss in 3 years). Share price has been volatile over the past 3 months (17% average weekly change).
공시 • Mar 26+ 1 more updateGenelux Corporation and Newsoara BioPharma Co., Ltd. Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung CancerGenelux Corporation and Newsoara BioPharma Co. Ltd. announced preliminary safety and anti-tumor activity data from the dose escalation Phase 1b portion of the companies' co-sponsored ongoing Phase 1b/2 clinical trial (OLVI-VEC-SCLC-202) of Olvi-Vec immunochemotherapy in patients with platinum-relapsed or platinum-refractory extensive small cell lung cancer. Olvi-Vec-SCLC-202 is a Phase 1b/2, open-label, multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics and efficacy of intravenously delivered Olvi-Vec combined with platinum and etoposide in the treatment of platinum-relapsed or platinum -refractory extensive small cell Lung cancer patients. The Phase 1b trial is currently enrolling patients in China at Shanghai Chest Hospital, the lead clinical site, and Zhejiang Provincial People's Hospital. The Phase 2 portion of the trial is planned to follow and further evaluate the safety and tolerability as well as efficacy of Olvi-Vec at the recommended dose. Olvi-Vec (olvimulogene nanivacirepvec), Genelux's most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials.
공시 • Mar 25Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory DiseaseGenelux Corporation announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/refractory ovarian cancer (PRROC). Currently, Olvi-Vec is being evaluated in the OnPrime/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival (Clinicaltrials.gov identifier NCT05281471). The purpose of the FDA meeting was to discuss the FDA's expectations with respect to the requirements necessary for the granting of traditional approval of Olvi-Vec. In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing On Prime/GOG-3076 trial, the FDA responded that "As stated previously, an interim analysis of overall survival (OS) should be planned at the time of the primary PFS analysis. If a clinically meaningful PFS advantage is demonstrated in the absence of a decreement in OS, this could potentially support traditional approval. The FDA further recommended Genelux request a pre-BLA meeting with FDA with topline safety and efficacy data following completion of the study to discuss next steps. The inclusion criteria allows patients to enroll regardless of (i) tumor biomarkers, (ii) platinum refractory tumors or (iii) the maximum number of prior lines of treatments (i.e., no cap on previous treatments). Olvi-Vec (olvimulogene nanivacirepvec), Genelux's most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec for the treatment of multiple types of cancer based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. To date, Olvi-Vec has been administered to more than 150 patients in seven completed clinical trials. Olvi-Vec has be granted Fast Track designation by the US FDA for the treatment of platinum resistant/refractory ovarian cancer.
분석 기사 • Feb 13Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Feb 03Genelux Corporation Appoints Matthew Pulisic as Chief Financial OfficerGenelux Corporation announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. Mr. Pulisic is an accomplished, senior executive with over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia. He is recognized for his expertise in financial leadership, corporate strategy and operational execution.Most recently, Mr. Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company. He played a key role in shaping the company’s financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company’s evolution from a clinical-stage to a pre-commercial organization. He began his career at Amgen, a publicly traded commercial biotechnology company, as a Research Associate and transitioned into finance where he held positions of increasing responsibility, across a breadth of finance-related positions, including Finance Director of Amgen Worldwide and Head of Capital Finance. He graduated from California Lutheran University with his M.B.A. in finance and from the University of California, Santa Cruz with his B.S. in Biochemistry and Molecular Biology.
Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.89 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.892 to -US$0.885 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$18.80 to US$18.40. Share price fell 16% to US$2.46 over the past week.
Seeking Alpha • Oct 31Genelux: H2 2025 PRROC Data Is A Major Inflection PointSummary Topline results from the phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer are expected in the second half of 2025. Interim data from the phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected in mid-2025. Interim results from the phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected second half of 2024. The global ovarian cancer treatment drugs market size is expected to reach $5.45 billion by 2033; About 85% of patients with ovarian cancer will experience recurrence at some point. Read the full article on Seeking Alpha
Price Target Changed • Oct 29Price target decreased by 9.6% to US$18.80Down from US$20.80, the current price target is an average from 5 analysts. New target price is 508% above last closing price of US$3.09. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.16 last year.
공시 • Oct 25Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung CancerGenelux Corporation announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies. The VIRO-25 clinical trial (NCT06463665 [3]), is an open-label, randomized study in NSCLC designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of ICI compared with docetaxel in patients with advanced or metastatic NSCLC who have shown first disease progression while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care. Olvi-Vec’s previous data suggests a manageable safety profile, and this trial looks to further confirm the hypothesis that Olvi-Vec may resensitize to platinum in multiple tumor types. Genelux expects interim data readout in mid-2025.
Recent Insider Transactions • Aug 29Insider recently sold US$200k worth of stockOn the 27th of August, Aladar Szalay sold around 92k shares on-market at roughly US$2.19 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$13m more than they bought in the last 12 months.
분석 기사 • Aug 24We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Major Estimate Revision • Aug 21Consensus EPS estimates upgraded to US$0.88 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.957 to -US$0.88 per share. Revenue forecast unchanged from US$0 at last update. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$23.50 unchanged from last update. Share price was steady at US$2.05 over the past week.
New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$22m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (US$8.0k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (US$73.2m market cap).
공시 • Jul 03+ 3 more updatesGenelux Corporation(NasdaqCM:GNLX) dropped from Russell Small Cap Comp Value IndexGenelux Corporation(NasdaqCM:GNLX) dropped from Russell Small Cap Comp Value Index
공시 • Jun 18Genelux Corporation, Annual General Meeting, Aug 01, 2024Genelux Corporation, Annual General Meeting, Aug 01, 2024.
공시 • May 25Genelux Corporation has completed a Follow-on Equity Offering in the amount of $27.5 million.Genelux Corporation has completed a Follow-on Equity Offering in the amount of $27.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,875,000 Price\Range: $4 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,875,000
공시 • May 24Genelux Corporation has filed a Follow-on Equity Offering.Genelux Corporation has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Security Name: Warrants Security Type: Equity Warrant
Reported Earnings • May 10First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.53 loss in 1Q 2023)First quarter 2024 results: US$0.29 loss per share (improved from US$0.53 loss in 1Q 2023). Net loss: US$7.85m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Recent Insider Transactions • Apr 19Insider recently sold US$256k worth of stockOn the 17th of April, Aladar Szalay sold around 71k shares on-market at roughly US$3.59 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$13m more than they bought in the last 12 months.
New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$93.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$170k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (US$93.0m market cap).
Price Target Changed • Apr 03Price target decreased by 23% to US$26.00Down from US$33.75, the current price target is an average from 4 analysts. New target price is 435% above last closing price of US$4.86. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$1.16 last year.
Reported Earnings • Mar 31Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.16 loss per share (further deteriorated from US$0.57 loss in FY 2022). Net loss: US$28.3m (loss widened 443% from FY 2022). Products in clinical trials Phase I: 3 Phase III: 1 Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 6.7%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
분석 기사 • Jan 29We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Dec 17Insider notifies of intention to sell stockYong Yu intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$13.16, it would amount to US$428k. Since March 2023, Yong's direct individual holding has decreased from 150.00k shares to 32.54k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Dec 10Insider recently sold US$436k worth of stockOn the 7th of December, Yong Yu sold around 37k shares on-market at roughly US$11.85 per share. This transaction amounted to 53% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.9m. Insiders have been net sellers, collectively disposing of US$12m more than they bought in the last 12 months.
Recent Insider Transactions • Nov 24Insider recently sold US$210k worth of stockOn the 20th of November, Yong Yu sold around 18k shares on-market at roughly US$11.60 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.9m. Insiders have been net sellers, collectively disposing of US$12m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Nov 20Insider notifies of intention to sell stockYong Yu intends to sell 37k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of November. If the sale is conducted around the recent share price of US$13.02, it would amount to US$479k. Since March 2023, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Oct 27Insider recently sold US$998k worth of stockOn the 23rd of October, Aladar Szalay sold around 50k shares on-market at roughly US$19.97 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$1.9m. Insiders have been net sellers, collectively disposing of US$11m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Oct 26Insider notifies of intention to sell stockYong Yu intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of October. If the sale is conducted around the recent share price of US$19.42, it would amount to US$101k. Since December 2022, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Oct 12Insider notifies of intention to sell stockYong Yu intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of October. If the sale is conducted around the recent share price of US$23.79, it would amount to US$124k. Since December 2022, Yong's direct individual holding has decreased from 150.00k shares to 106.14k. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Sep 27We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Sep 15Genelux Corporation Elects John Smither as Class I DirectorGenelux Corporation announced that at its 2023 Annual Meeting of Stockholders held on September 11, 2023, elected John Smither as Class I Director, to serve until the Company’s 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Recent Insider Transactions • Sep 13Insider recently sold US$879k worth of stockOn the 8th of September, Aladar Szalay sold around 37k shares on-market at roughly US$23.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.
New Risk • Sep 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$35m net loss in 3 years). Significant insider selling over the past 3 months (US$915k sold).
Recent Insider Transactions • Aug 31Insider recently sold US$489k worth of stockOn the 30th of August, Yong Yu sold around 20k shares on-market at roughly US$24.70 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$914k more than they bought in the last 12 months.
공시 • Aug 30Genelux Corporation Announces Executive ChangesOn August 28, 2023, Genelux Corporation announced the appointment of Lourie Zak as the Company’s Chief Financial Officer and the designation of Ms. Zak as the Company’s principal financial officer and principal accounting officer, in each case effective as of August 28, 2023 (the “Effective Date”). In connection with Ms. Zak’s appointment to the position of Chief Financial Officer, and as of the Effective Date, Thomas Zindrick, the Company’s President and Chief Executive Officer, will no longer serve as the Company’s principal financial officer, and Doug Samuelson, the Company’s former Chief Financial Officer, will no longer serve as the Company’s principal accounting officer. Ms. Zak, 60, most recently served as an Executive Consultant for CFO Assignments from March 2015 to August 2023. Ms. Zak previously served as the Chief Financial Officer of Guitar Center Brands of Guitar Center Inc. from October 2014 to January 2015 and the Chief Financial Officer of SONIFI Solutions Inc. from February 2013 to October 2014. Pursuant to the terms of Ms. Zak’s employment agreement (the “Zak Employment Agreement”), effective as of the Effective Date, Ms. Zak’s employment may be terminated at-will by either party, with or without notice, subject to the terms of the Zak Employment Agreement. Ms. Zak will receive a base salary of $360,000 per year and be eligible for an annual discretionary bonus with a target amount of up to 40% of her then-current base salary based on the achievement of certain performance goals determined by the Board of Directors of the Company. Subject to approval by the Board of Directors of the Company, Ms. Zak will be issued an option to purchase 150,000 shares of common stock of the Company with a per share exercise price equal to the fair market value on the date of grant (the “Option”). The shares subject to the Option will vest over four years of continuous service to the Company, with 25% of the shares subject to the Option vesting on the first-year anniversary of the Effective Date, and the remaining shares vesting in equal monthly installments over the subsequent 36 months of continuous service thereafter. In the event of a change in control, as defined in the Company’s 2022 Equity Incentive Plan, and subject to Ms. Zak’s continuous service through such change in control, 100% of the shares subject to the unvested portion of the Option will accelerate and vest in full. The Option shall be governed in all respects by the terms of the Company’s 2022 Equity Incentive Plan, as amended, and the option agreement between Ms. Zak and the Company. Ms. Zak will be entitled to receive severance benefits in the event her employment is terminated by the Company without cause or if she resigns for good reason, provided she remains in compliance with the terms of the Zak Employment Agreement. In the event of such termination or resignation, Ms. Zak will receive (i) severance in a lump sum equal to twelve months of her then-current base salary plus her full target annual bonus for the calendar year in which such separation occurs (but only in connection with a separation occurring during the period beginning three months before and ending 18 months following a change in control), and (ii) up to twelve months of COBRA group health insurance continuation. The foregoing severance benefits are conditioned upon Ms. Zak signing and not revoking a separation agreement and release of claims by no later than the 60th day after the employment termination.
Recent Insider Transactions • Aug 24Chairman recently sold US$198k worth of stockOn the 18th of August, Thomas Zindrick sold around 8k shares on-market at roughly US$23.73 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Aug 21Chairman notifies of intention to sell stockThomas Zindrick intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of August. If the sale is conducted around the recent share price of US$23.90, it would amount to US$200k. Since September 2022, Thomas has not owned shares directly (This sale likely refers to shares that have not yet been received). There has only been one transaction (US$1.2k purchase) from insiders over the last 12 months.
New Risk • Aug 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 9.2% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$17m net loss in 2 years).
공시 • Jul 23Genelux Corporation, Annual General Meeting, Sep 11, 2023Genelux Corporation, Annual General Meeting, Sep 11, 2023, at 10:00 Pacific Standard Time. Location: 4500 Riverwalk Pkwy Riverside United States Agenda: To elect the one Class I director to hold office until the Company's 2026 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal; to ratify the selection by the Audit Committee of the Board of Directors of Weinberg & Company, P.A. as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023; and to conduct any other business properly brought before the Annual Meeting.
공시 • Jul 16Genelux Notifies the Nasdaq Stock Market that it Was Not in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)Genelux Corporation announced that due to the vacancy resulting from Mr. Gabe Woodward's resignation, the Audit Committee of the Board is now comprised of two independent directors. As a result, on July 12, 2023, the Company notified The Nasdaq Stock Market LLC (Nasdaq") that it was not in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the Rule"), which requires an audit committee comprised of at least three members, each of whom must satisfy the requirements for audit committee members under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. The Company expects to receive a letter from Nasdaq to formally notify the Company of its non-compliance with the Rule. The Company intends to rely on the cure provision in Nasdaq Listing Rule 5605(c)(4)(B), and intends to regain compliance with the Rule prior to the expiration of the applicable cure period specified in Nasdaq Listing Rule 5605(c)(4)(B).
공시 • Jul 15Genelux Announces Resignation of Gabe Woodward from the BoardOn July 10, 2023, Gabe Woodward notified the board of directors (the “Board”) of Genelux Corporation (the “Company”) of his decision to resign from the Board, effective July 12, 2023. Mr. Woodward’s resignation was made in the normal course of business at the request of his partnership now that the Company’s initial public offering has been completed, and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
공시 • Jul 11Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Frontiers in ImmunologyGenelux Corporation announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effort (MPE) due to either MPM or metastatic disease (non-small cell lung cancer or breast cancer). The study was completed at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density and increase in immune cell density, confirming the mechanism of action of both direct cytotoxic and immune-activating effects. Among all patients, median overall survival (OS) was 19.5 months. The median OS among patients who had malignant pleural mesothelioma (MPM) was 22 months. There were no dose-limiting toxicities or dose de-escalations, and the maximally tolerated dose was not reached. Therefore, a recommended dose was not established. Palliative interventions have traditionally been relied upon for alleviating symptoms and preventing the recurrence of MPE, which can disrupt cancer treatments for MPE patients. However, the effectiveness of systemic immune checkpoint inhibitor therapy, chemotherapy, or a combination of therapies in MPE patients has shown limited success. This Phase 1 clinical trial enrolled eighteen MPE patients [MPM (n=15), and metastatic breast or lung diseases (n=3), who underwent a dose escalating method of intrapleural administration of Olvi-Vec following drainage of MPE. The primary objective of this trial was to determine a recommended dose. The secondary objectives were to assess feasibility, safety and tolerability; evaluate viral presence in the tumor and serum as well as viral shedding in pleural fluid, sputum, and urine; and evaluate anti-vaccinia virus immune response. Treatment with Olvi-Vec at the dose of 1x107 plaque-forming units (PFU) to 6x109 PFU was feasible and safe, with no treatment-associated mortalities or dose-limiting toxicities. Olvi-Vec was detectable in tumor cells 2-5 days post-treatment, and treatment was associated with a decrease in tumor cell density and an increase in immune cell density as assessed by a pathologist blinded to the clinical observations. When matched tumor specimens were compared (n=4), tumor cell density score decreased from pre-treatment to post-treatment in all patients. Immune cell density score increased from pre-treatment to post-treatment in 3 of 4 patients.
공시 • Jun 30Genelux Corporation and TVAX Biomedical, Inc. Announces the Issuance of A United States Patent Covering the Combination of an Adoptive T Cell Therapy/Oncolytic Viral Cancer TreatmentGenelux Corporation and TVAX Biomedical, Inc. announced that the United States Patent and Trademark Office granted a patent claims methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT Immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT Immunotherapy. The rationale for V2ACT Immunotherapy stems from compelling scientific evidence that vaccination generates an immune response which increases the number of neoantigen-specific T cells in the body and that Olvi-Vec induces an acute inflammatory response that increases cancer tissue receptivity for the clinical effects of adoptively transferred neoantigen-specific effector T cells. This generates compelling support for the view that V2ACT Immunotherapy may safely achieve superior efficacies against a wide range of cancers. V2ACT capitalizes on the lead assets of both Genelux and TVAX as a combination therapy. Olvi-Vec has demonstrated systemic immunomodulation, an excellent safety profile, powerful immune modulation of the cancer microenvironment and well-documented anti-cancer effects over a wide range of cancers both in preclinical and Phase 2 clinical trials. TVAX Immunotherapy provides a unique neoantigen-specific adoptive T cell therapy, with an excellent safety profile and powerful anti-cancer effects on a wide range of cancers demonstrated in preclinical and Phase 2 clinical trials.
공시 • May 16Genelux Corporation announced that it expects to receive $33.30494 million in fundingGenelux Corporation announced a private placement to issue1,665,247 common shares at a price of $20.00 per share for the gross proceeds of approximately $33.30494 million. The initial closing of the private placement, in the amount of approximately $18 million in the aggregate, is expected to occur on or about May 19, 2023, subject to the satisfaction of customary closing conditions. Additional committed funds in the amount of approximately $15 million in the aggregate will be invested on or before November 15, 2023, at the same price as the initial closing investments.
공시 • Jan 27Genelux Corporation has completed an IPO in the amount of $15 million.Genelux Corporation has completed an IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42